Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

188.26 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities
From Charles River Laboratories International, Inc.
Via Business Wire
Discover which S&P500 stocks are making waves on Thursday.
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday. 
Via Chartmill
Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
3 Reasons to Avoid CRL and 1 Stock to Buy Instead
The past six months have been a windfall for Charles River Laboratories’s shareholders. The company’s stock price has jumped 60.1%, hitting $170.64 per share. This was partly due to its solid quarterly... 
Via StockStory
Winners And Losers Of Q2: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Charles River Laboratories (NYSE:CRL) and its peers. 
Via StockStory
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing
From Charles River Laboratories International, Inc.
Via Business Wire
Why Charles River Stock May Struggle In Its Final Phase
Adhishthana.com notes Charles River Stock is nearing its Phase 18, with momentum weakening and long-term outperformance looking unlikely. 
Via Benzinga
Charles River Laboratories (CRL) Stock Is Up, What You Need To Know
Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 2.6% in the afternoon session after the stock's positive momentum continued, as Barclays upgraded the company to Overweight... 
Via StockStory
What's going on in today's session: S&P500 movers
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday. 
Via Chartmill
Why Charles River Laboratories (CRL) Stock Is Up Today
Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 1.9% in the morning session after Barclays upgraded the company to Overweight from Equal-Weight and raised its price target. 
Via StockStory
Topics Government
Wondering what's happening in today's S&P500 pre-market session?
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers. 
Via Chartmill
7 Analysts Assess Charles River: What You Need To Know
 
Via Benzinga
Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tariffs. 
Via Benzinga
Topics Government
Wednesday's session: top gainers and losers in the S&P500 index
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
Which S&P500 stocks are moving on Wednesday?
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Masimo, Integra LifeSciences, CONMED, IQVIA, and Charles River Laboratories Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. The Trump administration is... 
Via StockStory
Topics Government World Trade
What's going on in today's session: S&P500 movers
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Mr Wonderful Kevin O'Leary Says Bitcoin, Ethereum Enough To 'Capture The Promise' Of Crypto, Advises Against 'Irrelevant' Tokens
Renowned investor Kevin O’Leary expressed his belief on Wednesday that owning only Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) can capture the majority of the cryptocurrency market’s volat 
Via Benzinga
Charles River Laboratories Announces Chief Financial Officer Transition
From Charles River Laboratories International, Inc.
Via Business Wire
Uncover the latest developments among S&P500 stocks in today's session.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
Exploring the top movers within the S&P500 index during today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer
From Charles River Laboratories International, Inc.
Via Business Wire
3 Unpopular Stocks That Concern Us
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
Breaking Down Charles River: 6 Analysts Share Their Views
 
Via Benzinga
This Thomson Reuters Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
2 Cash-Producing Stocks Worth Your Attention and 1 We Brush Off
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.